Wednesday, October 26, 2016
University of California Irvine (UCI) Doses First Patient in Phase IIa Clinical Trial Using Stemedica’s Stem Cells for Alzheimer’s disease
The Only Alzheimer’s Disease Clinical Trial Using Stemedica’s Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Continues Recruitment at UCI
http://welcomeicarea.org/proper-cover-page-for-lab-report/ http://los.org/buy/how-good-is-generic-cialis/7/ click here https://groups.csail.mit.edu/cb/paircoil2/?pdf=download-sample-resume-for-mca-freshers essay tutor https://thedsd.com/sat-essay-paper/ here term paper order helping students write research papers https://jansmith.com/httpessaysreasy-comaccountorder-14821/ follow site order research paper can i write documents on my ipad https://lunchbreak.org/write/cheap-letter-writers-for-hire-for-school/35/ prednisone bronchitis see url care child director resume robert yin case study research https://geneseelandlordassoc.org/category/aims-of-literature/44/ example of expository essay writing hillary clinton speech live stream here cialis 5mg bula go site source link follow http://www.cresthavenacademy.org/chapter/table-contents-research-paper/26/ heroo essays junior sap basis administrator resume https://cirict.org/website-that-writes-essays/ homework help with geography buy 10 mg cialis Lausanne, Switzerland — October 26, 2016
Stemedica International, SA, a leader in the development of innovative stem cell-based treatments for Alzheimer’s disease (AD), is pleased to announce it will share its latest preclinical data at the Society for Neuroscience 46th Annual Conference held from November 12-16 in San Diego, CA. SfN’s annual meeting is the premier venue for neuroscientists to present emerging science, learn from experts, collaborate with peers and explore new tools and technologies.
Tristan Bolmont, PhD, Chief Scientist at Stemedica International, will present work entitled “Stem cells treatment for Alzheimer’s disease.” The research shows that intravenous administration of Stemedica’s mesenchymal stem cells safely decreases aggregation of Abeta and tau hyperphosphorylation, two major neuropathological hallmarks of Alzheimer’s disease. Moreover, the stem cell delivery decreases neuroinflammation and microglia activity in the brain without side effects such as microhemorrhages and cerebral amyloid angiopathy. This research was conducted in conjunction with the École Polytechnique Fédérale de Lausanne (EPFL). In addition to Dr. Bolmont’s presentation, SfN will share a lay language summary with the media as part of Neuroscience 2016’s Hot Topics book and in the Neuroscience 2016 online press room.
“Stemedica International is excited that more and more scientists and researchers are becoming aware of our groundbreaking research,” says Dr. Nikolai Tankovich, MD, PhD, Stemedica International’s Executive Chairman. “In August 2016, one of the “Hot Line” late-breaking science sessions at the European Society of Cardiology (ESC) featured Stemedica International’s sister company CardioCell’s significant positive results in a Phase IIa chronic heart failure trial using Stemedica’s uniquely potent mesenchymal stem cells. SfN is a great venue for sharing our latest scientific results showing that stem cells may have the potential to benefit Alzheimer’s disease patients.“
Stemedica International’s preclinical research on APP/PS1 transgenic mice demonstrate that Alzheimer’s disease pathology is amenable to its proprietary therapeutic stem cell intervention. Stemedica International is the first company in the United States to receive FDA approval for a Phase IIa clinical trial treating Alzheimer’s disease using stem cells.
Emory University in Atlanta, Georgia and University of California, Irvine are actively recruiting for this important clinical trial. More information including enrollment details, can be found at https://clinicaltrials.gov/ct2/show/NCT02833792?term=stemedica&rank=1.
About Stemedica International S.A.
Stemedica International S.A. is a biotechnology company that develops therapeutic applications for the treatment and prevention of Alzheimer’s disease. The company is a subsidiary of Stemedica Cell Technologies, Inc., a global biotechnology company that manufactures adult allogeneic stem cells. Stemedica International has the worldwide rights to manufacture and distribute its parent company’s allogeneic, ischemia-tolerant mesenchymal stem cell (itMSC) and ischemia-tolerant neural stem cell (itNSC) lines and stem cell factors for Alzheimer’s disease. The company also has Swissmedic licenses to import, export and distribute Stemedica Cell Technologies’ cell lines worldwide for human use in approved clinical trials. Manufactured in compliance with cGMP standards, the stem cell lines have a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. For more information, visit www.stemedica-intl.com.
About Stemedica Cell Technologies Inc.
Stemedica Cell Technologies Inc. is a global biopharmaceutical company that manufactures best-in-class allogeneic adult stem cells and stem cell factors. The company is a government licensed manufacturer of cGMP, clinical-grade stem cells currently used in US-based clinical trials for acute myocardial infarction, chronic heart failure, cutaneous photoaging, ischemic stroke, Alzheimer’s disease and traumatic brain injury. Stemedica’s products are also used on a worldwide basis by research institutions and hospitals for pre-clinical and clinical (human) trials. Stemedica is currently developing additional clinical trials for other medical indications using adult, allogeneic stems cell under the auspices of the FDA and other international regulatory institutions. The company is headquartered in San Diego, California, and can be found online at www.stemedica.com.
Forward Looking Statements
This press release may contain forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance and you are cautioned not to place undue reliance on these forward-looking statements. These statements reflect the views of Stemedica as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Stemedica International, S.A.
David Cheatham, MBA
+41 (0)78 794 7232